Ataxia Clinical Trial Progresses to 48-Week Extension Phase
October 4, 2017
BIOHAVEN OPTIMISTIC FOR NEXT PHASE OF TRIAL DESPITE DISAPPOINTING TOPLINE DATA As NAF previously reported, BioHaven Pharmaceutical Holding Company Ltd. recently completed its 8-week trial of dosing for its drug compound trigriluzole. This is the largest clinical trial for Spinocerebellar Ataxia (SCA) to-date. During the 8-week randomization phase, either the compound Read More…
